
Cancer Management & Treatment | Cancer Research & Drug Trials
Cancer Therapy Advisor offers the latest cancer management and treatment info, cancer research news, and more for oncologists and medical professionals.
Oncology ICD-10 Codes - Cancer Therapy Advisor
Nov 22, 2024 · This is a comprehensive table of oncology ICD 10 codes used by researchers and healthcare professionals and personnel – nurses, medical coders, physicians, et al.
Hematemesis in Patients With Cancer
Nov 4, 2024 · Hematemesis (vomiting blood) is a serious symptom that indicates upper gastrointestinal (GI) bleeding. In patients with cancer, it often stems from tumor erosion, treatment-related complications ...
Oral Cancer Symptoms, Stages, and Treatment
Mar 19, 2025 · Oral cancer is a type of cancer that affects the mouth (oral cavity) and parts of the throat (pharynx). In 2025, an estimated 59,660 people in the United States will develop oral cancer, and ...
Positive Anti-Nuclear Antibody (ANA) Test - Cancer Therapy Advisor
Jan 17, 2019 · Differential Diagnosis Systemic lupus erythematosus (SLE): when active, usually a homogenous pattern on ANA or less commonly speckled, rim, or nucleolar
Liver Mass Symptoms and Evaluation - Cancer Therapy Advisor
Jan 17, 2019 · Evaluation and symptoms of a patient with a liver mass. The differential diagnosis of a liver mass is broad but can be easily narrowed down based on two factors that are usually known at the time ...
Side Effects of Radiation for Prostate Cancer - Cancer Therapy …
Sep 6, 2024 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Prostate cancer remains the most common cancer in men, affecting ...
Oncology Drug Approvals, March 2025 - Cancer Therapy Advisor
Apr 7, 2025 · In March, the US Food and Drug Administration granted new approvals for Imfinzi (durvalumab), Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Cabometyx (cabozantinib), Gozellix (kit for the ...
Luveltamab Tazevibulin Proves Active in FRα+ Platinum-Resistant …
Mar 18, 2025 · Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer, according to a presentation at the SGO 2025 Annual ...
ASH 2024: Advances in CLL/SLL - Cancer Therapy Advisor
Dec 17, 2024 · Trial results presented at the ASH Annual Meeting 2024 could prompt changes in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), experts say.